HMGB1 inhibits cell death in yeast and mammalian cells and is abundantly expressed in human breast carcinoma

Marie-Luise Brezniceanu(Georg Speyer Haus), Kirsten Völp(Georg Speyer Haus), Susanne Bösser(Georg Speyer Haus), Christine Solbach(Goethe University Frankfurt), Peter Lichter(German Cancer Research Center), Stefan Joos(German Cancer Research Center), Martin Zörnig(Georg Speyer Haus)
The FASEB Journal
May 20, 2003
Cited by 190

Abstract

Apoptosis is a fundamental biological process used to eliminate unwanted cells in a multicellular organism. An increasing number of regulatory proteins have been identified that either promote or inhibit apoptosis. For tumors to arise, apoptosis must be blocked in the transformed cells, for example by mutational overexpression of anti-apoptotic proteins, which represent attractive target proteins for molecular therapy strategies. In a functional yeast survival screen designed to select new anti-apoptotic mammalian genes, we have identified the chromosomal high-mobility group box-1 protein (HMGB1) as an inhibitor of yeast cell death induced by the pro-apoptotic Bcl-2 family member Bak. The C-terminal 33 amino acids of HMGB1 are dispensable for this inhibitory function. HMGB1 is also able to protect mammalian cells against different death stimuli including ultraviolet radiation, CD95-, TRAIL-, Casp-8-, and Bax-induced apoptosis. We found high HMGB1 protein levels in human primary breast carcinoma. Hmgb1 RNA levels are changing during different stages of mouse mammary gland development and are particularly low during lactation and involution. These data suggest that HMGB1 may participate in the regulation of mammary gland apoptosis and that its high expression level promotes tumor growth because of its anti-apoptotic properties.


Related Papers

No related papers found

Powered by citation graph analysis